



Ogier in Jersey advises Medicxi on close of EUR200 million fund

Deals - 24/09/2020

Ogier in Jersey advises Medicxi on close of EUR200 million fund

Ogier's Jersey investment funds team, led by Niamh Lalor, has advised Medicxi on the close of its first secondary fund, Medicxi Secondary I (**MS1**), which raised €200 million. Ogier has advised Medicxi since its spin out from Index Ventures back in 2016.

MS1 was established to acquire six portfolio companies from Index Ventures Life VI (IL6), a life sciences fund advised by Medicxi. The portfolio was acquired from IL6 at a premium to its net asset value and was anchored by leading secondary investor, Pantheon (London), with LGT Private Equity (Pfaffikon, Switzerland) as co-lead investor. MS1 has committed to fund and accelerate the portfolio's development plans through to the next stages of value creation. IL6 investors received proceeds from the sale and were offered the opportunity to re-invest into MS1.

Niamh Lalor commented: "We were delighted to work with Medicxi on this innovative secondary transaction and launch of MS1. These types of deals, which are unprecedented in the biotech industry, are increasingly challenging to execute during a global pandemic. It was reassuring to see so many parties working remotely but nonetheless collaboratively across jurisdictions to facilitate a swift and seamless closing."

The Ogier team worked with lead counsel Travers Smith on the transfer of the portfolio and the launch of MS1. The team included Sophie Reguengo, Alexandra O'Grady, Joanna Christensen and Brooke Lewis.

About Ogier

Ogier is a professional services firm with the knowledge and expertise to handle the most

demanding and complex transactions and provide expert, efficient and cost-effective services to all our clients. We regularly win awards for the quality of our client service, our work and our people.

Disclaimer

This client briefing has been prepared for clients and professional associates of Ogier. The information and expressions of opinion which it contains are not intended to be a comprehensive study or to provide legal advice and should not be treated as a substitute for specific advice concerning individual situations.

Regulatory information can be found under [Legal Notice](#)

Meet the Author



Niamh Lalor

Partner

Jersey

E: niamh.lalor@ogier.com

T: [+44 1534 514210](tel:+441534514210)

Key Contacts



Sophie Reguengo

Partner

Jersey

E: sophie.reguengo@ogier.com

T: [+44 1534 514122](tel:+441534514122)



Alexandra O'Grady

Managing Associate

Jersey

E: alexandra.o'grady@ogier.com

T: [+44 1534 514081](tel:+441534514081)



Joanna Christensen

Counsel

Jersey

E: joanna.christensen@ogier.com

T: [+44 1534 514127](tel:+441534514127)



Brooke Lewis

Associate

Jersey

E: brooke.lewis@ogier.com

T: [+44 1534 514074](tel:+441534514074)

Related Services

[Investment Funds](#)

[Legal](#)

Related Sectors

[Funds Hub](#)